Design Therapeutics Inc
Research Design Therapeutics Inc (DSGN) on Bullrun: market cap USD 981.26M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDSGN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 981.26M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 20.17M
- Free cash flow-USD 15.55M
Valuation Snapshot
latest market cap is USD 981.26M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 69.79M | -USD 54.55M | n/a | -1.22 | USD 16.86M | USD 1.54M | USD 212.50M |
| FY2024 | USD 0 | -USD 49.59M | -USD 43.45M | n/a | -0.88 | USD 22.56M | USD 2.33M | USD 242.10M |
| FY2023 | USD 0 | -USD 66.86M | -USD 58.82M | n/a | -1.19 | USD 21.20M | USD 3.05M | USD 277.69M |
| FY2022 | USD 0 | -USD 58.62M | -USD 52.24M | n/a | -1.14 | USD 26.50M | USD 3.99M | USD 327.31M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 981.26M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 566.53M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 350.17M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 148.41M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 573.64M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.19B | n/a | n/a | n/a |
About Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Design Therapeutics Inc's market cap?
Design Therapeutics Inc's market capitalization is USD 981.26M.
What does Design Therapeutics Inc do?
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.